Toremifene is a selective estrogen receptor modulator (SERM) and a chlorinated derivative of tamoxifen, primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It works by binding to estrogen receptors and exhibiting both antiestrogenic effects in breast tissue and some estrogenic agonist properties in other tissues like bone and cardiovascular system. Unlike tamoxifen, toremifene appears to have a more favorable safety profile regarding endometrial effects while maintaining similar efficacy in breast cancer treatment.

Research

Safety Profile

Safety Profile: Toremifene

Common Side Effects

• Hot flashes (the most common side effect, occurring in up to 35% of patients)
• Nausea, vomiting, and gastrointestinal discomfort
• Vaginal discharge, vaginal dryness, and irregular menstruation
• Sweating and flushing
• Peripheral edema and weight changes
• Dizziness and fatigue
• Elevated liver enzymes (transient and usually asymptomatic)

Serious Adverse Effects

• QT prolongation and cardiac arrhythmias: Toremifene carries a risk of QTc prolongation that may lead to torsades de pointes; ECG monitoring recommended, especially in patients with risk factors
• Thromboembolic events: Increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke, similar to other selective estrogen receptor modulators (SERMs)
• Endometrial changes: Endometrial hyperplasia, polyps, and rarely endometrial cancer with long-term use
• Hepatotoxicity: Elevated liver enzymes; rare cases of significant hepatic injury
• Hypercalcemia: May occur in patients with bone metastases, particularly during initial treatment
• Ocular effects: Corneal keratopathy, cataracts, and visual disturbances reported with prolonged use

Contraindications

• Known hypersensitivity to toremifene or any excipients
• History of or existing thromboembolic disease (DVT, PE, stroke) unless benefits clearly outweigh risks
• Pre-existing QT prolongation, uncorrected hypokalemia or hypomagnesemia, or concurrent use of QT-prolonging drugs
• Endometrial hyperplasia or unexplained vaginal bleeding
• Severe hepatic impairment
• Pregnancy (FDA Category D) and lactation; may cause fetal harm

Drug Interactions

• QT-prolonging drugs (antiarrhythmics, fluoroquinolones, macrolide antibiotics, antipsychotics): Additive QT prolongation; avoid combination or monitor ECG closely
• CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin): Increase toremifene plasma levels; heightened risk of QT prolongation
• CYP3A4 inducers (rifampin, phenytoin, carbamazepine): Decrease toremifene levels; may reduce efficacy
• Anticoagulants (warfarin): SERMs may potentiate anticoagulant effects; monitor INR
• Thiazide diuretics: May worsen hypokalemia, increasing QT prolongation risk

Population-Specific Considerations

• Postmenopausal women with breast cancer: Primary indication (metastatic ER+ breast cancer); monitor endometrial thickness and thromboembolic risk
• Elderly: Increased cardiovascular and thromboembolic risk; ECG and electrolyte monitoring essential
• Men (off-label use): Used off-label for gynecomastia prevention during testosterone or anabolic steroid use; monitor liver function and lipids
• Cardiac patients: Avoid in patients with significant cardiac history; obtain baseline ECG and correct electrolyte abnormalities before starting
• Hepatic impairment: Reduced clearance; avoid in severe impairment; monitor liver function in mild-moderate impairment

Pharmacokinetic Profile